SCHEMBL2462677

SCHEMBL2462677

Nc1c(Cl)cc(N2CCCC2)c2c1C(=O)c1ccccc1C2=O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 10/20 0.54
▸ L3MBTL1 Q9Y468 10/20 0.54
▸ MAPK1 P28482 6/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ EGFR P00533 2/20 0.54
▸ RAF1 P04049 1/20 0.54
▸ ALOX12 P18054 1/20 0.54
▸ MAP2K1 Q02750 1/20 0.54
▸ NSD2 O96028 4/20 0.49
▸ CYP1A1 P04798 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ LMNA P02545 2/20 0.44
▸ POLB P06746 7/20 0.43
▸ KMT2A Q03164 7/20 0.43
▸ MEN1 O00255 5/20 0.43
▸ TDP1 Q9NUW8 5/20 0.43
▸ THRB P10828 3/20 0.43
▸ S100A4 P26447 1/20 0.43
▸ ADORA2A P29274 1/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9354579 0.79 MAPT (0.56) MAPTL3MBTL1MAPK1ALDH1A1EGFR
SCHEMBL582033 0.76 CYP1A1 (0.72) MAPTL3MBTL1MAPK1ALDH1A1CYP1A1
SCHEMBL9921188 0.76 MAPT (0.52) MAPTL3MBTL1MAPK1ALDH1A1EGFR
SCHEMBL7769609 0.75 ADORA2A (0.62) MAPTL3MBTL1MAPK1ALDH1A1CYP1A1
SCHEMBL11180975 0.72 FTO (0.59) MAPTL3MBTL1MAPK1ALDH1A1NSD2
SCHEMBL6055375 0.72 CYP1A1 (0.57) MAPTL3MBTL1MAPK1ALDH1A1ALOX12
SCHEMBL2464584 0.72 L3MBTL1 (0.74) MAPTL3MBTL1MAPK1ALDH1A1EGFR
SCHEMBL2463193 0.70 MAPT (1.00) MAPTL3MBTL1MAPK1ALDH1A1EGFR
SCHEMBL8777879 0.70 MAOA (0.67) MAPTL3MBTL1MAPK1ALDH1A1ALOX12
SCHEMBL3273424 0.69 MAPT (0.97) MAPTL3MBTL1MAPK1ALDH1A1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2019-01-24 — — US disclosed
US-10098887-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2018-10-16 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY INC (US) 2016-05-12 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-9173886-B2 Antiviral compounds and methods of use thereof TRANA DISCOVERY, INC. (US) 2015-11-03 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TRANA DISCOVERY, INC (US) 2013-03-21 — — US disclosed
WO-2011113060-A2 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TRANA DISCOVERY, INC. (US) 2011-09-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10098887-B2 Antiviral compounds and methods of use thereof TYMP, MAVS, ZC3HAV1 MAPT 3443/4885L3MBTL1 528/4885MAPK1 2803/4885
US-20160129006-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MAPT 3443/4885L3MBTL1 528/4885MAPK1 2803/4885
US-20130071353-A1 Antiviral Compounds and Methods of Use Thereof TYMP, MAVS, ZC3HAV1 MAPT 3443/4885L3MBTL1 528/4885MAPK1 2803/4885
US-20190022100-A1 ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF TYMP, MAVS, ZC3HAV1 MAPT 3443/4885L3MBTL1 528/4885MAPK1 2803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback